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Abstract
Objectives—The purpose of the present study was to develop and validate noninvasive 
bioluminescence imaging methods for differentially monitoring primary and abdominal metastatic 
tumor growth in mouse orthotopic models of pancreatic cancer.
Methods—A semiautomated maximum entropy segmentation method was implemented for the 
primary tumor region-of-interest, and a rule-based method for manually drawing a region-of-
interest for the abdominal metastatic region was developed for monitoring tumor growth in 
orthotopic models of pancreatic cancer. The two region-of-interest methods were validated by 
having two observers independently segment Panc-1 tumors, and the results compared with the 
number of mesenteric lymph node nodules, and histopathological assessment of liver metastases. 
The findings were extended to orthotopic tumors of the more metastatic MIA PaCa-2 and AsPC-1 
cells where separate groups of animals were implanted with different numbers of cells.
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Results—The results demonstrated that the segmentation methods were highly reliable, 
reproducible and robust, and allowed statistically significant discrimination in the growth rates of 
primary and abdominal metastatic tumors of different cell lines implanted with different numbers 
of cells.
Conclusions—The present results demonstrate that primary tumors and abdominal metastatic 
foci in orthotopic pancreatic cancer models can be reliably quantified separately and 
noninvasively over time with bioluminescence imaging.
Keywords
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NSG Mice
Pancreatic ductal adenocarcinoma (PDAC) has a very poor prognosis and is currently the 
fourth leading cause of cancer death in the United States.1 PDAC patients have a median 
survival of 6 months and a 5-year survival rate of 5%.2,3 The lethal nature of PDAC is 
strongly associated with metastases to distant organs.4,5 Rapid autopsy evaluation of patients 
who died of PDAC revealed that over 70% had metastases, most commonly to the liver and 
then lung.6 Conventional approaches of surgical resection, radiation, and/or chemotherapy 
fail to prevent local recurrence and metastasis, most likely because of preexisting 
micrometastases at initial diagnosis.4,7–9 Improved strategies for detecting, and ultimately 
treating, early and metastatic stages of the disease are therefore urgently needed, including 
in preclinical orthotopic models of pancreatic cancer.
Several approaches have been developed for assessing metastatic burden in preclinical 
models of pancreatic cancer. Zeidman et al.10 pioneered the method of counting the number 
of metastases under a dissecting microscope at necropsy. Another approach has been to 
count the number of metastatic foci on histology sections.e.g.,11 Rather than count individual 
metastatic foci, some investigations have simply reported the percentage of mice with 
visible foci.e.g.,12–14 More recently, Hotz15,16 developed a comprehensive dissemination 
score calculated based on the extent of local infiltration, distant metastases, and clinical 
signs of tumor burden. Studies using bioluminescence imaging (BLI), utilizing pancreatic 
cancer cells stably transfected with luciferase, have predominantly quantified only the 
primary or the whole body total tumor burden17–21 in vivo. However, metastatic tumor 
burden has been quantified in several BLI studies after necropsy by homogenizing target 
tissues and measuring the bioluminescence signal ex vivo.e.g.19 In addition, orthotopic 
models with pancreatic tumor cells stably transfected with fluorescent proteins have been 
used to monitor primary tumor growth in vivo and metastases at necropsy ex vivo.22–24 
While all of these approaches have provided valuable insights into pancreatic tumor biology 
and potential new treatment regimens, ex vivo approaches have the limitation of being 
invasive with respect to monitoring metastases, which requires the use of a relatively large 
number of animals since cohorts must be sacrificed at individual time points. The above ex 
vivo approaches also do not allow separate monitoring of primary tumor and metastases over 
time in individual animals. Methods for noninvasively monitoring primary and metastatic 
tumor growth differentially over time in vivo are needed to better understand not only the 
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dynamics of tumor growth of primary tumors and metastatic foci, but also to provide 
methods to monitor novel treatments over time in individual animals.
The purpose of the present study was to develop and validate noninvasive BLI methods for 
uniquely segmenting primary from metastatic tumors in mouse orthotopic models of 
pancreatic cancer in order to separately monitor primary and metastatic tumor growth 
noninvasively over time. A semiautomated maximum entropy25,26 segmentation method 
was implemented for primary tumor region-of-interest (ROI) designation, and a rule-based 
method was developed for manually drawing and designating the ROI for the metastatic 
region. Both ROI methods were validated in the following manner. First, two observers 
independently segmented the images of the tumors of animals implanted orthotopically with 
the relatively less metastatic Panc-1 cells14,21 expressing a luciferase-EGFP fusion protein. 
The results were compared with the number of mesenteric lymph node nodules counted 
following necropsy and histopathological assessment of liver metastases. We elected to 
utilize a relatively less aggressive cell line for validating the ROI methods based on the 
reasoning that it was necessary to determine whether relatively lower levels of metastases 
could be detected, and that this information would be informative in interpreting results on 
the appearance, or lack thereof, and growth rate of metastases with more aggressive cell 
lines. Second, the findings with Panc-1 cells were extended to orthotopic tumors of the more 
aggressive and metastatic MIA PaCa-2 and AsPC-1 cells where different groups of animals 
were implanted with different numbers of pancreatic cells to determine if the present 
segmentation methods allowed discrimination between the growth rates of different cell 
lines and implantation of different cell numbers. The results demonstrated that our 
segmentation methods were highly reproducible and relatively sensitive, allowing for 
statistically significant discrimination in the growth of the primary and metastatic tumors of 
different cell lines implanted with different cell numbers.
MATERIALS AND METHODS
Cell lines
Panc-1, AsPC-1 and MIA PaCa-2 cells were purchased from American Type Culture 
Collection and cultured as instructed by the vendor. The cell lines were analyzed by IDEXX 
RADL (Columbia, MO) and the authenticity of each line was confirmed to be human, have 
no cross-contamination, and correct at the molecular level via microsatellite marker analysis.
Transduction of cell lines with lentiviral vectors expressing luciferase/fluorescent protein 
fusion proteins
Panc-1 cells were transduced with the lenti viral vector pCL6LucEGwo containing a fusion 
protein of the human codon usage-optimized luciferase cDNA (InvivoGen, San Diego, CA) 
and the cDNA for the enhanced green fluorescent protein (Clontech). AsPC-1 and MIA-
PaCa-2 cells were transduced with the lentiviral vector pCL6LucCHwo which contains a 
fusion protein of the human codon usage-optimized luciferase cDNA and the cDNA for 
mCherry (Clontech). Details on the vector and cloning will be available elsewhere (Wiek, 
Hanenberg, Pollok, unpublished). The fusion mRNA is expressed off a modified promoter 
from the U3 region of the SFFV retrovirus.27 Replication-incompetent infectious lentiviral 
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particles in the vesicular stomatitis virus glycoprotein (VSV-G) pseudotype (kindly obtained 
from Dirk Lindemann, Dresden, Germany) were generated using 293T cells as previously 
described27 and high viral titers were obtained (~109 transduction units per ml). Cell lines 
were transduced one time with frozen supernatants at a multiplicity-of-infection (MOI) of 
100 in the presence of 8 μg/ml polybrene and analyzed for EGFP (Panc-1) or mCherry (MIA 
PaCa-2, AsPC-1) expression by flow cytometry (BD LSR Cell Analyzer, BD Biosciences, 
San Jose, CA).
Chemicals
D-Luciferin-K+ (Caliper Lifescience USA) was prepared in phosphate buffered saline to 
yield a final concentration of 20 mg/ml (pH 7), and was stored in individual light tight 
aliquots at −20°C until use.
Animals
All studies were carried out in accordance with, and approval of, the Institutional Animal 
Care and Use Committee of Indiana University School of Medicine, and the Guide for the 
Care and Use of Laboratory Animals.28 Male and female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 
(NSG) mice were obtained from the In Vivo Therapeutics Core of the Indiana University 
Simon Cancer Center. Animals were maintained under pathogen-free conditions and 
maintained on Teklad Lab Animal Diet (TD 2014, Harlan Laboratories USA) with ad 
libitum access to sterile tap water under a 12-hour light-dark cycle at 22–24 °C.
Survival surgery
Mice were anesthetized with 5% isoflurane in oxygen. An incision (1–1.5 cm) was created 
in the left abdominal flank under aseptic conditions. The pancreas was carefully exposed 
and 50 μl of cell solution in phosphate buffered saline were injected into the tail of the 
pancreas as previously described29 (Panc-1: 2 × 106 cells, N = 34; MIA PaCa-2 and 
AsPC-1: 2 × 104 or 2 × 105 cells, N = 6/group). The peritoneum and fascia were closed in 
separate layers using a continuous 4/0 Prolene suture; the skin wound was closed using a 
wound clip.
In vivo Imaging
Beginning on day 7 post tumor implantation and continuing weekly thereafter, dynamic 
bioluminescence images were acquired using a Berthold NightOwl (BL981, Berthold 
Technologies Inc. USA) imaging system outfitted with a 24W inductive header (RH-7, Zoo 
Med Laboratories Inc.) and a custom anesthesia manifold supporting up to 3 mice per 
session. Prior to imaging, the skin over the abdomen and left lateral epigastric regions were 
shaved and depilated with Nair (Church and Dwight Inc., USA). Anesthetic induction was 
achieved with 2–4% isoflurane, and animals were administered D-luciferin (150 mg/kg) 
subcutaneously. Mice were immediately transferred to the heated stage (40±1 °C) of the 
Imager, placed on their backs, and sequentially imaged at 2 min intervals for 40 mins with 
image integration times ranging from 1 to 120 sec/image. At the completion of the sequence, 
anatomical reference photos were acquired permitting generation of fused image sets.
Shannon et al. Page 4
Pancreas. Author manuscript; available in PMC 2016 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
In order to validate the ROI methods (see Image Analysis), 34 mice with Panc-1 orthotopic 
tumors were utilized. All mice were imaged on day 7 or 8 (i.e., baseline) after implant and 
then block randomized (using a random number list), by flux density at the time of peak 
light emission in the primary ROI, to imaging groups to balance the initial tumor burden of 
the primary tumors across groups. One animal was excluded from the study due to lack of 
signal above background at baseline (final N = 33). One group of nine mice was imaged 
weekly to monitor changes in tumor burden over time in the same animals. Additional 
separate groups of 6 mice each were imaged only once, on day 7 or 8, 14, 20 or 28, and then 
necropsied the following day. When prominent metastases had not yet developed by day 28, 
the original design was modified in order to allow time for metastases to develop and the 
remaining 9 mice, rather than being imaged on day 35, were randomly assigned to be 
imaged on either day 43, 50 or 57 (3/day), and necropsied the following day.
Following necropsy, the number of mesenteric lymph node metastatic nodules was counted 
and ex vivo GFP imaging using a Bright Light System Illumatool LT9900 (LightTools 
Research, Encinitas, CA) was used to visualize primary tumor and metastases. The livers 
were then fixed in 10% neutral buffered formalin for at least 24 hours and then embedded in 
paraffin, sectioned, and stained with H&E and Ki67 using standard immunohistochemical 
techniques and 3,3′-diaminobenzadine as chromagen. Morphometric analysis of Ki67 
staining was done with an Aperio Whole Slide Imaging System (Aperio Technologies, 
Vista, CA) using the Aperio software Positive Pixel Count Algorithm under the supervision 
of a board certified pathologist. Images of stained sections were captured with ImageScope 
v11.2.0.780 (Aperio Technologies). We also sought to determine if the method could be 
used to monitor more aggressive tumors, and to detect differences in tumor burden due to 
implantation of different numbers of cells. The orthotopic model described above with 
Panc-1 cells was again utilized. Groups of 6 mice each were implanted orthotopically with 2 
× 104 or 2 × 105 AsPC-1 or MIA PaCa-2 cells; one mouse implanted with 2 × 104 MIA 
PaCa-2 cells died perioperatively for a final N of 5 for this group. Mice were imaged weekly 
for up to 8 weeks to monitor changes in primary and metastatic tumor burden over time in 
the same animals. For these studies, mice were placed on their sides for the first image on 
day 7 in order to better image the primary tumor; thereafter, they were placed on their backs 
and the ventral surface imaged. Thus, the baseline scan for the primary tumor of these 
animals was day 7, and for the metastases it was day 14.
Image Analysis
To provide visualization, segmentation and time series quantification from the 40-min scan, 
BLI and anatomical reference images were imported into custom-developed software. 
Pseudo-colored parametric overlays of BLI time-series with anatomical reference images 
were dynamically constructed for each animal. Using the image of the time series with the 
peak light emission for each individual animal, ROIs were designated for both primary 
tumors and a metastatic region. Primary tumors were segmented through time using the 
semi-automated maximum entropy ROI algorithm.25 For metastatic tumors, ROIs of the 
abdomen were manually drawn which encompassed the dome of the liver and extended to 
the animal’s inferior inguinal aspect which included the genitals (see also Fig. 1). To avoid 
photon spillover from the primary to the metastasis ROI (and vice versa), the manual ROIs 
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maintained an approximate 3 mm offset from the primary tumor on all lateral aspects across 
all 20 imaging time points. Occasionally (particularly when tumors were small) 
gastrointestinal motility resulted in movement of the tumor. When gastrointestinal motility-
induced (or rarely, animal motion-induced) movement of the primary tumor occurred, the 
manual ROIs were adjusted to maintain a 3 mm offset from any location of the primary on 
any of the 20 BLI imaging frames. The extracted time series were then analyzed for total 
emission flux (Ph/sec), average emission flux density (Ph/sec*mm2) and area (mm2) at the 
peak of the time course kinetics according to:
(1)
(2)
(3)
(4)
where IT, Ip, n, m, IA and t are the total emission flux density (Ph/s*mm2), pixel emission 
flux density, subject, total number of pixels, average emission flux density, and time points, 
respectively. Moreover, DA, FT and A are the average emission flux density, total emission 
flux at the peak of the time course, and ROI area, respectively. To minimize the role of 
tumor and animal motion on time course parameters, individual ROIs across image frames 
were aligned by computing the per frame center of gravity30 offset between successive 
frames, and applying the x-y offset to the ROI prior to computing IT or IA described in 
equations 1 or 2, respectively.
Data Analysis
Each ROI was independently constructed by two observers (BPM and HES). The 
interobserver reliability of the measurements was determined by Pearson product-moment 
correlations. To evaluate if the difference between pairs of measurements increased as the 
mean of the pairs increased, the correlation between the two values was determined with a 
homoscedasticity plot;31 differences were not correlated with mean values when 
transformed logarithmically, as recommended.31,32 In order to determine the reproducibility 
of the measurements, the coefficients of variation were calculated for each animal for each 
pair of images; the coefficient of variation was calculated as the ratio of the standard 
deviation of the log of the two ROI measurements to the mean of the log of the two ROI 
measurements. Limits of agreement (Bland-Altman) plots31 were constructed from the 
logarithmically transformed data, and the limits of agreement calculated31,32 according to:
(5)
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where LOA, SDD, and X̄G are the limits of agreement, standard deviation of the difference, 
and grand mean respectively. Tumor volumes/bioluminescence signals, ROI areas and the 
number of lymph node nodules were analyzed by a 1- or 2-way ANOVA, as appropriate, 
using SigmaPlot 11.2 (Systat Software, Inc).
RESULTS
Visualization of abdominal metastases
Abdominal metastases were typically not readily visible on standard BLI images until foci 
were relatively large in size (see Fig. 1 and also Fig 6). However, the visualization of the 
bioluminescence signal from the abdominal metastases could be enhanced by adjusting the 
manner in which the pseudocolor was mapped to the photon flux density scale (see Fig. 1A1 
and A2). The adjustment was accomplished by compressing the color scale so that lower 
flux densities were represented by “higher/brighter” colors, or to a color rather than ‘no 
color’, on the fused overlays of the BLI signal on the anatomical images. Following 
adjustment of the color mapping, bright spots of smaller metastatic foci became visible, and 
disseminated micrometastases were visible as diffuse coloring (Fig. 1A2). With these 
considerations in mind, we sought to quantitate the bioluminescence signals in the primary 
and metastasis ROIs.
Validation of ROI methods in Panc-1 orthotopic tumors
The primary tumor and abdominal metastases increased over time in mice with Panc-1 
orthotopic tumors as measured by bioluminescence (Fig. 2; see also Fig. 6A). We initially 
examined the total flux in each region. Total flux is the sum of the light emitted from all of 
the luciferase expressing cells in a region, and is indicative of the total number of cells in a 
region, regardless of whether those cells are widely dispersed or clustered together. When 
the data were expressed as the total photon flux (Ph/sec) in the ROIs for the primary tumor 
and metastases (Fig. 2A), the total flux within the metastasis ROI was larger in magnitude 
than the total flux from the primary tumor ROI, at times by as much as several orders of 
magnitude, indicating that there were more luciferase expressing cells in the metastasis ROI 
than in the primary ROI. Total flux was statistically significantly larger in magnitude for the 
metastases than for the primary as indicated by a significant main effect for Tumor ROI 
(F(1,164) = 176.5, p < 0.001; two-way ANOVA). The total flux of both primary and 
metastatic tumors increased over time as indicated by a significant main effect for Days 
(F(6,164) = 56.7, p < 0.001; two-way ANOVA). Further, the slopes of the growth curves for 
the primary and metastatic tumors were different as indicated by a significant Tumor ROI x 
Day interaction (F(6,164) = 36.7, p < 0.001; two-way ANOVA). We also compared 
luciferase-EGFP fusion protein expressing PANC-1 cells and the parental cells on the rate of 
tumor growth and metastatic tumor progression, and did not find significant differences 
(data not shown), indicating that ectopic expression of this fusion protein did not affect the 
potential of tumor growth and metastases in PANC-1 cells.
As expected, the area (in mm2) of the ROIs for the primary tumors significantly increased 
over days post implantation (mean±SD across all days: 23.9±16.9 mm2) as evidenced by a 
significant main effect for days (F(7,81) = 10.6, p < 0.001; one-way ANOVA), whereas the 
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areas of the ROIs for the metastases were constant over days (1167±111 mm2) as evidenced 
by a non-significant main effect for Days (F(7,81) = 1.9, p > 0.05; one-way ANOVA). To 
examine the average amount of light emitted per unit of area in both regions, indicative of 
the compactness or density of the light-emitting cells, the data were expressed as the average 
flux density (Ph/sec*mm2) within the ROIs. In contrast to the findings with total flux, the 
density of the flux within the smaller primary tumor ROI was larger in magnitude than the 
density of the flux from the larger metastases ROI (Fig. 2B), by as much as several orders of 
magnitude. That is, although there were substantially fewer total photons emitted from the 
primary than the metastatic region, there were more photons per mm2 emitted from the 
primary region compared with the metastatic region, consistent with the cells in the primary 
tumor being clustered much more closely together than in the metastatic region. Flux density 
was statistically significantly larger in magnitude in the primary than the metastatic ROI 
(F(1,164) = 248.4, p < 0.001; two-way ANOVA). Moreover, the flux density of both primary 
and metastatic tumors increased over time as indicated by a significant main effect for Days 
(F(6,164) = 39.0, p < 0.001; two-way ANOVA). In addition, the slopes of the growth curves 
measured by flux density for the primary and metastatic tumors were significantly different 
as indicated by a significant Tumor ROI x Day interaction (F(6,164) = 34.5, p < 0.001; two-
way ANOVA).
Metastatic burden was also monitored following necropsy of animals at each time point and 
counting the number of mesenteric lymph node nodules, histopathological assessment of 
liver sections, and visualization of GFP intensity in livers. The number of lymph node 
nodules increased over time (Fig. 2C; F(6,32) = 21.0, p < 0.001), and the number of nodules 
was significantly increased on days 50 and 57 (p < 0.05, Dunnett’s test vs Day 7). In 
comparison, the total photon flux in the metastases ROI was significantly increased from 
day 29 post implantation onwards (Fig. 2A). Livers from animals imaged on day 29 and then 
necropsied were assessed to be normal upon histopathological assessment, but focal and 
multifocal metastases increased thereafter, with the size of metastases ranging from 
approximately 8 to 10 cells to as many as approximately 150 cells/metastasis, and with 
increasing Ki67 index values (data not shown and Fig. 3A, B), concordant with the BLI 
data. Similarly, visualization of GFP expression indicated no apparent metastases on day 29 
but increasing abundance of metastases through day 57 post-implant (Fig. 3C), again 
concordant with the BLI data.
The interobserver reliability of the measurements was determined by Pearson product-
moment correlations (Fig. 4). Total flux and flux density from ROIs for the primary tumors, 
constructed using the semi-automated maximum entropy algorithm,25 were highly 
concordant (r = 0.999 and r = 0.997, respectively) between the two observers (Fig. 4A,C). 
Moreover, total flux and flux density from ROIs for the metastases, constructed manually, 
were also highly concordant (r = 0.988 and r = 0.992; Fig. 4B, D). In addition, the slopes of 
the correlations were very close to 1.0, indicating that the two observers were also in close 
agreement.
Absolute reliability is the degree to which repeated measurements vary for individuals and 
can be measured using the coefficient of variation and limits of agreement.31,32 The 
coefficients of variation for the total photon flux (Ph/sec) were approximately 0.19 and 0.20 
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for the primary and metastases, and were approximately 0.05 and 0.20, respectively, for the 
photon flux density (Ph/sec*mm2), indicating an acceptably small dispersion in the data. 
The agreement between the ROIs of the two observers was also quantified from Bland-
Altman plots (Fig. 5). For both the primary and metastases ROIs, the bias, or average 
difference between the two observers, was relatively negligible (Fig. 5, dotted lines) and was 
approximately 0.028 and 0.016 log units for the total flux and flux density for the primary 
tumor ROIs, and was approximately 0.040 and 0.024 log units, respectively, for the 
metastases ROIs. Limits of agreement are expected to contain the difference between two 
measurements for 95% of pairs of future measurements on similar individual subjects.31 The 
limits of agreement values were approximately 3.5% and 2.3% for the total photon flux (Ph/
sec) for the primary and metastases measurements, and 1.5% and 4.9% for the photon flux 
density (Ph/sec*mm2) measurements. Taken together, the present findings indicate that the 
ROI segmentation methods developed in the present study for constructing ROIs for the 
primary pancreatic tumor and abdominal metastases are valid, reproducible, and reliable.
MIA PaCa-2 and AsPC-1 orthotopic tumors
We next sought to extend the findings with Panc-1 cells to orthotopic tumors of the more 
aggressive and metastatic MIA PaCa-2 and AsPC-1 cells to determine if the present 
segmentation methods allowed discrimination between the growth rates of different cell 
lines and implantation of different cell numbers.
In mice with MIA PaCa-2 orthotopic tumors, the primary tumor and metastases increased 
over time after implantation with either 2 × 104 or 2 × 105 cells (Fig. 6B and Fig. 7), and 
with a cell number-related decrease in survival (Table 1). MIA PaCa-2 cells grew more 
rapidly, compared with Panc-1 cells, and also produced a cell number-related decrease in 
survival (Table 1). When the data were expressed as total flux (Ph/sec), there was a 
significant increase across days both for the primary tumor (F(6,64) = 3.9, p = 0.002) and 
metastases (F(5,54) = 25.8, p < 0.001). Moreover, the overall difference in the magnitude of 
the signals between the two cell numbers (2 × 104 or 2 × 105 cells per mouse) implanted for 
the primary tumor was not significant (F(1,64) = 3.2, p = 0.08; Fig. 7A) but was statistically 
significant for the metastases (F(1,54) = 63.9, p < 0.001; Fig. 7B). Post-hoc analyses, 
however, indicated that growth of the primary tumors was significantly greater than baseline 
on day 42 for the group of mice implanted with 2 × 105 cells (Fig. 7A). Further, on days 35 
and 42, the BLI signal of the metastases was significantly different from the baseline (Fig. 
7B). When the data were expressed as the average density of the flux (Ph/sec*mm2), there 
was again a significant increase across days both for the primary tumor (F(6,64) = 17.0, p < 
0.001; Fig. 7C) and metastases (F(5,54) = 13.3, p < 0.001; Fig. 7D). The overall difference in 
signal for the two cell numbers implanted was significantly different for the primary tumor 
(F(1,64) = 12.4, p < 0.001; Fig. 7C) as well as for the metastases (F(1,54) = 24.6, p < 0.001; 
Fig. 7D). Post-hoc analyses indicated that for flux density, the primary tumor was 
significantly increased from baseline on days 49 – 56 for the 2 × 104 cells group and on days 
29 – 42 for the 2 × 105 cells group (Fig. 7C). In comparison, on days 35 – 42 for the 2 × 105 
cells group, flux density for the metastases was significantly different from baseline; 
however, for the group of mice implanted with 2 × 104 cells, no significant difference from 
baseline was observed on any day (Fig. 7D). Analyses of inter-observer reliability, 
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coefficients of variation, and limits of agreement for MIA PaCa-2 orthotopic tumors were 
similar to those for Panc-1 orthotopic tumors (data not shown). The present data with MIA 
PaCa-2 orthotopic pancreatic tumors demonstrate that our segmentation methods can 
discriminate between the growth rates of different numbers of cells implanted, and that flux 
density is the superior measure for primary tumors while total flux is the superior measure 
for metastases.
In mice with AsPC-1 orthotopic tumors, the primary tumor and metastases again increased 
over time after implantation with either 2 × 104 or 2 × 105 cells (Fig. 6C and Fig. 8). 
AsPC-1 cells grew more aggressively than either Panc-1 or MIA PaCa-2 tumors, with a 
greater cell number-related decrease in survival than Panc-1 or MIA PaCa-2 (Table 1). 
When the data were expressed as total flux (Ph/sec), there was a significant increase across 
days both for the primary tumor (F(5,46) = 7.1, p < 0.001) and metastases (F(4,37) = 11.8, p < 
0.001). Moreover, the overall difference in the magnitude of the signals between the two cell 
numbers was significant for both the primary tumor (F(1,46) = 15.8, p < 0.001; Fig. 8A) as 
well as for the metastases (F(1,37) = 7.1, p = 0.012; Fig. 8B). Post-hoc analyses indicated that 
growth of the primary tumors measured by total flux was not significantly different from 
baseline on any day for the 2 × 104 cells group but was significantly different from baseline 
on day 42 for the 2 × 105 cells group (Fig. 8A). Further, growth of the metastases was 
significantly different from the baseline scan on day 42 for the 2 × 104 cells group and on 
days 35 – 42 for the 2 × 105 cells group (Fig. 8B). In contrast, when the data were expressed 
as the density of the flux (Ph/sec*mm2), there was a significant increase across days both for 
the primary (F(5,46) = 51.1, p < 0.001) and metastases (F(4,37) = 10.7, p < 0.001). In addition, 
the overall difference in signal for the two cell numbers implanted was significantly 
different for the primary tumor (F(1,46) = 7.3, p = 0.01; Fig. 8C) as well as for the metastases 
(F(1,37) = 4.2, p = 0.048; Fig. 8D). Post-hoc analyses indicated that for flux density, the 
primary tumor was significantly different from baseline on day 42 for the 2 × 104 cells 
group and on days 29 – 42 for the 2 × 105 cells group (Fig. 8C, D). In comparison, flux 
density for the metastases was not significantly different from the baseline on any day for 
the 2 × 104 cells group but was significant on day 42 for the 2 × 105 cells group (Fig. 8C, 
D). Analyses of interobserver reliability and limits of agreement for AsPC-1 orthotopic 
tumors were similar to those for Panc-1 and MIA PaCa-2 orthotopic tumors (data not 
shown). The present data with AsPC-1 orthotopic pancreatic tumors provide further 
confirmation that the segmentation methods used here discriminate the growth rates of 
different cell lines, and also confirms that these methods can discriminate the growth rates of 
different numbers of cells implanted. Our data with AsPC-1 tumors also confirm that flux 
density is the superior measure of the relatively more compacted primary tumors while total 
flux is the superior measure of the relatively more dispersed metastases.
DISCUSSION
Current approaches for assessing metastatic growth in preclinical orthotopic models of 
pancreatic cancer largely rely on quantification of metastases after necropsy, which can 
require large numbers of animals and precludes investigation of metastatic growth over time, 
and/or following pharmacologic or other treatments within individual animals. In the present 
study, we developed strategies for longitudinally and noninvasively monitoring primary and 
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metastatic tumor burden separately by BLI. We demonstrated that a primary tumor ROI can 
be reliably constructed using a semi-automated maximum entropy algorithm.25 Further, we 
demonstrated that a metastasis ROI, inclusive of the entire abdomen but exclusive of an 
approximately 3 mm region around the primary ROI, can be reliably constructed manually. 
The present results demonstrated that, utilizing these ROIs, primary and metastatic tumor 
burden can be noninvasively monitored longitudinally, and, the approach is sensitive enough 
to distinguish growth rates of orthotopic tumors not only between cell lines, but also 
between tumors initiated by implantation of different numbers of cells.
We utilized several measures of reliability and reproducibility in the present study. The 
interobserver reliability was assessed by correlation of the ROI signals constructed 
independently by two observers. The correlation coefficients were generally greater than 
0.99, indicating a very high degree of reliability, and, the slopes of the correlations were 
close to 1.0, indicating good agreement between the two observers. The absolute reliability 
of the ROI measurements, as assessed by the coefficient of variation on logarithmically 
transformed data, ranged from approximately 0.05 to 0.20, which was well within 
acceptable limits. The limits of agreement, expected to contain the difference between two 
measurements for 95% of pairs of future measurements on similar individual subjects,31 was 
also within acceptable limits (1.5%– 5%) when the data were logarithmically transformed. 
The need to transform the data was not unexpected: as previously noted,32 it is common for 
the variability in biological data to increase as the magnitude of the mean increases. 
Intuitively, this is due to numbers closer to zero tending to cluster together more closely, 
while numbers further from zero are generally less closely clustered. Thus, we conclude that 
the methods of segmentation of primary and metastatic tumor burden presented herein are 
reliable and reproducible.
Data from BLI studies may be expressed either as total luminance flux in the ROI, expressed 
as Ph/sec, or as luminance flux density in the ROI, expressed as photons/sec/unit of area. 
Both methods of expression have biological significance. Total flux aggregates the photons 
emitted from dispersed cells expressing luciferase, whereas flux density can indicate the 
localized density of cells expressing luciferase. In the present studies, we found that the 
primary tumor appears to be best visualized and analyzed when data are expressed as the 
density of the BLI signal. The present finding is consistent with the primary tumor being 
localized in a relatively small area and thus it is primarily the density of the tumor cells and 
their photon emission that changes over time with growth, even though the total number of 
photons may be relatively small in magnitude. On the other hand, we found that the 
metastasis burden appears to be best visualized and analyzed by the total flux, thereby 
aggregating, or summating, the more diffuse signals from small clusters of cells as occurs in 
metastatic disease. It is the spread of relatively small clusters of metastatic tumor cells that 
primarily changes over time more so than density. Studies are in progress to assess this 
innovative analysis methodology in the context of conventional and novel treatments for 
pancreatic cancer.
In the present study, we found that the total bioluminescence signal (in Ph/sec) in the 
metastases ROI was as much as several orders of magnitude larger than the signal from the 
primary tumor ROI. It is not uncommon for studies to use whole body BLI to monitor what 
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is generally interpreted as primary tumor growth. However, the present data indicate that 
such an interpretation could be incorrect and potentially misleading. Rather, the signal from 
whole body imaging is a mixture of signal from the primary tumor and the metastases, and 
the signal from the metastases has the potential to overwhelm the signal from the primary 
when measured as total photon flux (in Ph/sec). This observation is consistent with the 
observation of Graeser and coworkers19,20 who previously suggested that with whole body 
BLI (using MIA PaCa-2 and AsPC-1 orthotopic models), the signal from the abdominal 
metastases can disproportionately contribute to the overall bioluminescence signal, and can 
contribute to the signal ascribed to the primary tumor. Taken together, these observations 
indicate that bioluminescence data from whole body imaging without segmentation, 
particularly when both primary tumor and metastases are present, should be interpreted with 
caution.
The present findings directly comparing the growth rates and metastatic potential of 
orthotopically implanted Panc-1, MIA PaCa-2 and AsPC-1 pancreatic cancer cell lines 
extend previous findings with these cell lines. Loukopoulos et al.14 directly compared the 
tumorigenicity and rate of metastasis of 10 different pancreatic cell lines, including Panc-1 
and AsPC-1, after orthotopic implantation in NSG mice. The AsPC-1 cell line was 
somewhat more tumorigenic and produced a larger percentage of animals with peritoneal 
dissemination and lymph node metastases than did Panc-1 cells when animals were 
necropsied at time of morbidity or 100 days after implantation, consistent with the present 
findings in NSG mice. Torgenson et al.33 found that implantation of 1 × 106 MIA PaCa-2 
and AsPC-1cells had similar growth characteristics at 2 and 5 weeks after orthotopic 
injection in nude mice (Ncr-Nu/Nu), whereas we found that AsPC-1 cells were somewhat 
more aggressive than MIA PaCa-2 cells in NSG mice. Further, Hotz et al.16 found that 
orthotopic injection of AsPC-1 cells resulted in 100% tumor development, whereas injection 
of MIA PaCa-2 cells resulted in 83% tumor take and progression of disease, consistent with 
the present results. Although differences in methodology, e.g., number of cells injected, 
indicate that comparisons among studies should be interpreted with caution, the data taken 
together suggest that AsPC-1 cells are at least somewhat more tumorigenic and have a 
higher rate of metastases than MIA PaCa-2 and Panc-1 cells when implanted into the 
pancreas. Most importantly, from this study we show that we are able to detect, and quantify 
differences, in primary tumor growth and distant metastases for these 3 pancreatic cancer 
cell lines non-invasively over time with reliability and reproducibility. In the present study, 
an area of at least 3 mm around the primary tumor was excluded from both the primary and 
metastases ROIs to avoid counting photons emitted from the primary tumor in the 
metastases ROI (and vice versa). This region likely contains tumor cells, but signal from 
these were not included in the present analyses. Whether the cells in this region should be 
excluded to avoid cross-contamination of signals, included with the primary as a growth 
edge, included with the metastases, or considered as a separate localized infiltration region is 
a topic for future studies specifically designed to address this question from imaging as well 
as histological and other approaches. In addition, the total flux in the metastases ROI was 
likely underestimated, in part due to the 3 mm border around the primary, but also because 
we chose to exclude from the metastases ROI any portion of the abdomen into which the 
primary moved. Nevertheless, the occurrence and growth of metastases was reliably 
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measured in the present study, and the underestimation of the total flux of the metastasis 
region does not appear to have been a substantive issue.
In summary, the present study demonstrated that primary tumors and abdominal metastatic 
foci in orthotopic pancreatic cancer models can be reliably monitored and quantified 
separately and noninvasively over time with bioluminescence imaging. A semiautomated 
maximum entropy segmentation method was validated for primary tumor ROI designation. 
A rule-based method for manually drawing and designating the ROI for the metastatic 
region was also validated. The results of the present study demonstrated that the present 
segmentation methods were not only highly reliable, reproducible and robust but also 
relatively sensitive, allowing statistically significant discrimination in the growth rates of the 
primary and metastatic tumors of different cell lines implanted with different numbers of 
cells. The novel segmentation methods reported here will facilitate investigations of the 
biology of primary and metastatic tumor growth, as well as the effects of novel treatments, 
over time in individual animals.
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Figure 1. 
(A1 and A2) Illustration of ROIs and color mapping for primary and abdominal metastatic 
regions of bioluminescence images in an animal implanted orthotopically with Panc-1 cells 
and imaged 34 days post implant. In A1, the pseudocolor was mapped to the photon flux 
density scale using a typical rainbow scale where the highest flux density in the image was 
mapped to red, and the color transitioned through the colors of the rainbow, and then to ‘no 
color’ (i.e., transparent on the fused overlay of the BLI image on the anatomical image, thus 
allowing the anatomical image to be seen) as the flux density decreased (see scales to the 
left of A1). With this color mapping approach, the magnitudes of the photon flux densities in 
the metastatic foci and micrometastases were too small to be mapped to a color, and 
therefore were not visible, until a focus become relatively large (see B). In order to enhance 
the visibility of metastases, in A2 the color mapping to the flux density scale was 
compressed to approximately 18% of full scale, such that 0 – 18% of the full flux density 
scale was mapped to rainbow color transitions, and 18 – 100% of full scale was mapped to 
red (see color scale to the right of A2). The flux density scales are the same in both A1 and 
A2; the panels differ only in the manner in which the pseudocolor was mapped to the flux 
density scale. The red arrows indicate the primary ROI, the green arrows indicate the 
metastasis ROI, and blue arrows indicate metastatic foci in both panels. (B1 and B2) 
Example of correspondence between a large metastatic focus on a bioluminescence image 
and tumor growth observed at necropsy (orange arrows) in an animal implanted 
orthotopically with 2 × 105 AsPC-1 cells and imaged 35 days post implant. The red arrow 
indicates the primary ROI and the green arrow indicates the metastasis ROI.
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Figure 2. 
Growth of primary tumor and abdominal metastatic burden in mice orthotopically implanted 
with Panc-1 cells. Data are expressed either as the total flux in photons/sec in each ROI (A), 
the average flux density in photons/sec*mm2 (B), or as the average number of lymph node 
nodules (C). *p < 0.05 vs. baseline, Holm-Sidak post-hoc test.
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Figure 3. 
Representative histological and green fluorescent protein images of liver metastases from 
mice orthotopically implanted with Panc-1 cells. (A) Hematoxylin and eosin stained liver 
sections (magnification 5X). (B) Ki67 stained liver sections (magnification 5X). (C) Green 
fluorescent protein images of liver ex vivo. Images in each column are from the same 
animal. Scale bar in A, B = 400 μm.
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Figure 4. 
Interobserver correlations for the primary (A,C) and metastases (B,D) ROIs expressed as 
either total flux in photons/sec (A,B) or average flux density in photons/sec*mm2 (C,D) 
from mice orthotopically implanted with Panc-1 cells. Data from all animals for all of the 8 
weekly imaging sessions were included in the correlations.
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Figure 5. 
Limits of agreement (Bland-Altman) plots on logarithmically transformed data for the 
primary (left panels) and metastasis (right panels) ROIs expressed as either total flux in 
photons/sec (A,B) or average flux density in photons/sec*mm2 (C,D) from mice 
orthotopically implanted with Panc-1 cells. Data from all animals for all of the 8 weekly 
imaging sessions were included in the plots. Each point represents the difference between 
observer 1 (ROI1) and observer 2 (ROI2) for an individual animal. The abscissa is the mean 
of the two observations. The bias (mean difference between the two observers across all 
animals) is indicated by the dashed red line and the 95% confidence limits are indicated by 
the dashed blue lines.
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Figure 6. 
Representative bioluminescence images of animals implanted orthotopically with either 2 × 
106 Panc-1 (A), 2 × 105 MIA Paca-2 (B) or 2 × 105 AsPC-1 (C) pancreatic tumor cells. 
Numbers above the panels are the days post implant for the Panc-1 tumors and numbers 
below the panels are the days post implant for the MIA PaCa-2 and AsPC-1 tumors.
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Figure 7. 
Growth of primary tumor and abdominal metastases in mice orthotopically implanted with 
MIA PaCa-2 cells. Data are expressed either as the total flux in photons/sec in each ROI (A, 
B) or as the average flux density in photons/sec*mm2 (C, D). *p < 0.05 vs. baseline, Holm-
Sidak post-hoc test. N = 6/group unless otherwise indicated in parentheses.
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Figure 8. 
Growth of primary and abdominal metastases in mice orthotopically implanted with AsPC-1 
cells. Data are expressed either as the total flux in photons/sec (A, B) or as the average flux 
density in photons/sec*mm2 (C, D). *p < 0.05 vs. baseline, Holm-Sidak post-hoc test. N = 5 
for the 2 × 104 group and N = 6 for the 2 × 105 group unless otherwise indicated in 
parentheses.
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